Barclays Lowers Danaher (NYSE:DHR) Price Target to $240.00

Danaher (NYSE:DHR) had its target price lowered by Barclays from $275.00 to $240.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the conglomerate’s stock.

DHR has been the topic of several other research reports. JPMorgan Chase & Co. reduced their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday. Citigroup dropped their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. TD Cowen upped their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Jefferies Financial Group reduced their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Stock Performance

Danaher stock opened at $223.16 on Thursday. Danaher has a 52-week low of $221.34 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a fifty day moving average price of $235.89 and a two-hundred day moving average price of $253.45. The firm has a market capitalization of $161.19 billion, a P/E ratio of 42.27, a P/E/G ratio of 4.22 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period last year, the firm earned $2.09 EPS. As a group, analysts anticipate that Danaher will post 8.15 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.48%. Danaher’s dividend payout ratio is currently 20.45%.

Institutional Trading of Danaher

A number of institutional investors have recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. bought a new position in shares of Danaher in the fourth quarter worth approximately $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Strategic Financial Concepts LLC purchased a new position in Danaher during the fourth quarter valued at $31,000. Finally, Pineridge Advisors LLC raised its position in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.